keyword
https://read.qxmd.com/read/38722307/real-life-effectiveness-of-antiviral-therapy-for-hcv-infection-with-pangenotypic-regimens-in-hiv-coinfected-patients
#1
JOURNAL ARTICLE
Anna Piekarska, Aleksandra Berkan-Kawińska, Hanna Berak, Włodzimierz Mazur, Marek Sitko, Anna Parfieniuk-Kowerda, Beata Lorenc, Dorota Dybowska, Ewa Janczewska, Justyna Janocha-Litwin, Beata Dobracka, Łukasz Socha, Magdalena Tudrujek-Zdunek, Robert Flisiak
BACKGROUND: The aim of this studywas to evaluate the real-life efficacy of pangenotypic antivirals inHIV-HCV-positive patients. RESEARCH DESIGN AND METHODS: The analysis included 5650 subjects who were treated with pangenotypicanty-HCV drugs: 5142 were HCV-positive and 508 were HIV-HCV-positive. RESULTS: Patients with HCV-monoinfection were older ( p  < 0.0001), however patients with HCV-monoinfection had a higher proportion of advanced fibrosis F4 ( p  < 0...
May 9, 2024: Expert Review of Anti-infective Therapy
https://read.qxmd.com/read/38722246/epidemiology-screening-and-co-management-of-type-2-diabetes-mellitus-and-metabolic-dysfunction-associated-steatotic-liver-disease
#2
JOURNAL ARTICLE
Xiaolong Qi, Jie Li, Cyrielle Caussy, Gao-Jun Teng, Rohit Loomba
Metabolic-dysfunction associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is increasingly recognized as a prevalent global burden. Type 2 diabetes mellitus (T2DM), another important metabolic disease, is considered a major contributor to the development of MASLD. MASLD and T2DM have a strong association with each other due to shared pathogenic mechanisms. The co-existence of the two diseases increases the risk of liver-related adverse outcomes, and imposes a heavier burden on extrahepatic outcomes, representing a substantial public health issue...
May 8, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38721946/mitochondria-regulated-information-processing-nanosystem-promoting-immune-cell-communication-for-liver-fibrosis-regression
#3
JOURNAL ARTICLE
Tingting Che, Xiaopeng Yang, Yuanyuan Zhang, Yin Zheng, Yufei Zhang, Xinge Zhang, Zhongming Wu
Liver fibrosis is a coordinated response to tissue injury that is mediated by immune cell interactions. A mitochondria-regulated information-processing (MIP) nanosystem that promotes immune cell communication and interactions to inhibit liver fibrosis is designed. The MIP nanosystem mimics the alkaline amino acid domain of mitochondrial precursor proteins, providing precise targeting of the mitochondria. The MIP nanosystem is driven by light to modulate the mitochondria of hepatic stellate cells, resulting in the release of mitochondrial DNA into the fibrotic microenvironment, as detected by macrophages...
May 9, 2024: Small
https://read.qxmd.com/read/38721807/direct-reprogramming-of-fibroblasts-into-functional-hepatocytes-via-crispra-activation-of-endogenous-gata4-and-foxa3
#4
JOURNAL ARTICLE
Jiacheng Li, Ruopu Li, Xue Bai, Wenlong Zhang, Yu Nie, Shengshou Hu
BACKGROUND: The ability to generate functional hepatocytes without relying on donor liver organs holds significant therapeutic promise in the fields of regenerative medicine and potential liver disease treatments. Clustered regularly interspaced short palindromic repeats (CRISPR) activator (CRISPRa) is a powerful tool that can conveniently and efficiently activate the expression of multiple endogenous genes simultaneously, providing a new strategy for cell fate determination. The main purpose of this study is to explore the feasibility of applying CRISPRa for hepatocyte reprogramming and its application in the treatment of mouse liver fibrosis...
May 9, 2024: Chinese Medical Journal
https://read.qxmd.com/read/38721579/alstrom-s-syndrome-an-experience-of-tertiary-care-center
#5
JOURNAL ARTICLE
Ghadah Gosadi, Maryam Busehail, Zuhair Rahbeeni
Alstrom's syndrome (AS) is an autosomal recessively inherited multisystemic disorder that falls under the umbrella of ciliopathy. It is characterized by poor vision, hearing impairment, cardiomyopathy, childhood obesity, diabetes mellitus type 2, dyslipidemia, pulmonary, hepatic, and renal failure besides systemic fibrosis. Biallelic pathogenic variants in ALMS1 gene cause AS. Retrospective study (1990-2017) included 12 Saudi patients with AS based on their phenotype, biochemical markers, and genotype. The study was approved by Fisal Specialist Hospital and Research Centre, Riyadh (RAC number 2131129) on October 2, 2012...
June 2024: Journal of Pediatric Genetics
https://read.qxmd.com/read/38720450/external-validation-of-models-to-predict-hepatocellular-carcinoma-in-hepatitis-c-virus-cured-f3-f4-patients
#6
JOURNAL ARTICLE
Ângela Carvalho-Gomes, Tsveta Vladi Valcheva Valcheva, Iván Sahuco, Enrique Vidal, Laura Martínez-Arenas, Carmen Vinaixa, Victoria Aguilera, Sónia García García, Marina Berenguer
BACKGROUND & AIMS: Several hepatocellular carcinoma (HCC) risk-models have been developed to individualise patient surveillance following sustained viral response (SVR) in Hepatitis C Virus patients. Validation of these models in different cohorts is an important step to incorporate a more personalised risk assessment in clinical practice. We aimed at applying these models to stratify the risk in our patients and potentially determine cost-saving associated with individualised HCC risk-stratification screening strategy...
May 8, 2024: United European Gastroenterology Journal
https://read.qxmd.com/read/38720191/impact-of-glp-1-receptor-agonist-use-in-patients-with-steatotic-liver-disease-and-type-2-diabetes-a-retrospective-cohort-study
#7
JOURNAL ARTICLE
Marci Wood, Amanda G Kennedy, Sidra Khan, Juvena R Hitt, Kayla Davis, Sheela S Reddy, Matthew P Gilbert
Background: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) help manage type 2 diabetes (T2DM) and may have efficacy in steatotic liver disease. Objective: To determine the prevalence and clinical impact of GLP-1 RA use in patients with T2DM and liver disease. Methods: This was a retrospective study of adult patients with T2DM and nonalcoholic fatty liver disease (NAFLD), nonalcoholic fatty liver (NAFL), or nonalcoholic steatohepatitis (NASH) between 1/1/21-12/31/21. Patients with hepatitis B or C, or on pioglitazone were excluded...
May 8, 2024: Journal of Pharmacy Practice
https://read.qxmd.com/read/38719623/outcomes-of-combined-liver-kidney-transplantation-single-center-experience
#8
JOURNAL ARTICLE
Michał Macech, Jolanta Małyszko, Sławomir Nazarewski, Małgorzata Kościelska, Piotr Krawczyk, Michał Grąt, Zbigniew Gałązka
BACKGROUND: There is continuous growth of combined liver-kidney transplantation (CLKTx) numbers with remarkable outcomes, especially among patient with liver cirrhosis and end-stage renal disease. The aim was to present a single center experience. METHODS: Twenty patients (9 males) with a mean age of 48 (range: 20-62) years underwent CLKTx from 2005 to 2022. Indications were polycystic liver and kidney diseases (ADPKD) in 12 cases, cirrhosis due to hepatitis (4 patients), and 1 case of amyloidosis, alcoholic liver disease, nonalcoholic steatosis, and congenital hepatic fibrosis with concomitant glomerulonephritis...
May 7, 2024: Transplantation Proceedings
https://read.qxmd.com/read/38718937/a-review-regarding-the-article-electrocardiographic-abnormalities-in-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease-a-systematic-review-and-meta-analysis
#9
REVIEW
Chao Li, Ting Wang, Jinbo Song
Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a high-risk condition for both liver fibrosis and cardiovascular disease (CVD). Therefore, therapeutic strategies to prevent both liver fibrosis and atherosclerotic CVD are required for the treatment of MASLD. Metabolic dysfunction-associated steatohepatitis (MASH) is the more severe form of MASLD, is defined histologically by the presence of lobular inflammation and hepatocyte ballooning and is associated with a greater risk of fibrosis progression...
May 6, 2024: Current Problems in Cardiology
https://read.qxmd.com/read/38718791/a-5-2-intermittent-fasting-regimen-ameliorates-nash-and-fibrosis-and-blunts-hcc-development-via-hepatic-ppar%C3%AE-and-pck1
#10
JOURNAL ARTICLE
Suchira Gallage, Adnan Ali, Jose Efren Barragan Avila, Nogayhan Seymen, Pierluigi Ramadori, Vera Joerke, Laimdota Zizmare, David Aicher, Indresh K Gopalsamy, Winnie Fong, Jan Kosla, Enrico Focaccia, Xin Li, Suhail Yousuf, Tjeerd Sijmonsma, Mohammad Rahbari, Katharina S Kommoss, Adrian Billeter, Sandra Prokosch, Ulrike Rothermel, Florian Mueller, Jenny Hetzer, Danijela Heide, Benjamin Schinkel, Tim Machauer, Bernd Pichler, Nisar P Malek, Thomas Longerich, Susanne Roth, Adam J Rose, Johannes Schwenck, Christoph Trautwein, Mohammad M Karimi, Mathias Heikenwalder
The role and molecular mechanisms of intermittent fasting (IF) in non-alcoholic steatohepatitis (NASH) and its transition to hepatocellular carcinoma (HCC) are unknown. Here, we identified that an IF 5:2 regimen prevents NASH development as well as ameliorates established NASH and fibrosis without affecting total calorie intake. Furthermore, the IF 5:2 regimen blunted NASH-HCC transition when applied therapeutically. The timing, length, and number of fasting cycles as well as the type of NASH diet were critical parameters determining the benefits of fasting...
May 2, 2024: Cell Metabolism
https://read.qxmd.com/read/38717914/hepatocellular-carcinoma-among-patients-with-chronic-hepatitis-b-in-the-indeterminate-phase
#11
REVIEW
Lung-Yi Mak, Leland J Yee, Robert J Wong, Christian B Ramers, Catherine Frenette, Yao-Chun Hsu
Hepatitis B virus (HBV) infection is a dynamic disease where patients progress through several stages defined by HBV e-antigen (HBeAg) status, HBV-DNA levels and transaminase elevations, with antiviral therapy indicated only in specific stages. However, some patients cannot be classified into one of the stages and are said to fall into an 'indeterminate phase' or 'grey zone'. Exact definitions of the indeterminate phase vary from guideline to guideline as a result of different cut-off values for biomarker measurements...
May 8, 2024: Journal of Viral Hepatitis
https://read.qxmd.com/read/38717690/mafld-identifies-patients-with-significant-hepatic-fibrosis-better-than-masld
#12
JOURNAL ARTICLE
Ziyan Pan, Said A Al-Busafi, Maheeba Abdulla, Yasser Fouad, Giada Sebastiani, Mohammed Eslam
BACKGROUND AND AIMS: Diagnostic criteria for metabolic dysfunction-associated steatotic liver disease (MASLD) have been proposed but not yet validated. This study aimed to compare the diagnostic accuracy of the MASLD definition with the existing criteria for metabolic dysfunction-associated fatty liver disease (MAFLD) in identifying patients with significant fibrosis. METHODS: The analysis included a total of 8317 individuals who had complete biochemical and liver ultrasonography data from the National Health and Nutrition Examination Survey (2017-2020)...
May 8, 2024: Hepatology International
https://read.qxmd.com/read/38716214/serum-zinc-concentration-as-a-potential-predictor-of-presarcopenia-in-patients-with-chronic-liver-disease-a-preliminary-study
#13
JOURNAL ARTICLE
Mitsuyuki Suzuki, Toru Ishikawa, Kazuki Ohashi, Asami Hoshii, Hiroshi Hirosawa, Hirohito Noguchi, Terasu Honma
BACKGROUND: Presarcopenia is a common complication of chronic liver disease. However, the relationship between serum zinc concentration and presarcopenia in patients with chronic liver disease remains unclear. Herein, we examined whether serum zinc concentration could predict presarcopenia in patients with chronic liver disease. METHODS: Between October 2015 and December 2019, 278 patients with chronic liver disease (median age, 68 years; women/men, 133/145; hepatitis B virus/hepatitis C virus/negative hepatitis B surface antigen and negative anti-hepatitis C virus antibody, 55/124/99) who underwent abdominal computed tomography (CT) and simultaneous measurement of serum zinc concentration were included...
2024: Translational Gastroenterology and Hepatology
https://read.qxmd.com/read/38715844/bystander-effects-and-profibrotic-interactions-in-hepatic-stellate-cells-during-hiv-and-hcv-coinfection
#14
JOURNAL ARTICLE
Cintia Cevallos, Patricio Jarmoluk, Franco Sviercz, Cinthya A M López, Rosa N Freiberger, M Victoria Delpino, Jorge Quarleri
This study aims to explore the influence of coinfection with HCV and HIV on hepatic fibrosis. A coculture system was set up to actively replicate both viruses, incorporating CD4 T lymphocytes (Jurkat), hepatic stellate cells (LX-2), and hepatocytes (Huh7.5). LX-2 cells' susceptibility to HIV infection was assessed through measurements of HIV receptor expression, exposure to cell-free virus, and cell-to-cell contact with HIV-infected Jurkat cells. The study evaluated profibrotic parameters, including programed cell death, ROS imbalance, cytokines (IL-6, TGF- β , and TNF- α ), and extracellular matrix components (collagen, α -SMA, and MMP-9)...
2024: Journal of Immunology Research
https://read.qxmd.com/read/38715676/a-case-report-of-intrahepatic-bile-duct-dilatation-caused-by-wdr19-gene-mutation-and-presented-as-caroli-syndrome
#15
Lingling Liu, Yuan Huang, Feng Fang, Hua Zhou, Xinglou Liu
BACKGROUND: Caroli syndrome or Caroli disease is characterized by focal dilation of the intrahepatic bile ducts, with or without congenital liver fibrosis. Mutations in the WDR19 gene can result in nephropathy, an autosomal recessive cystic kidney disease. However, this genetic mutation is clinically associated with Caroli syndrome or disease. We hypothesize that WDR19 gene mutations may contribute to extrarenal phenotypes such as Caroli disease or syndrome. CASE DESCRIPTION: The outpatient department received a 1-year-old male patient with persistent dilated bile ducts for over four months...
April 30, 2024: Translational Pediatrics
https://read.qxmd.com/read/38715329/galectin-3-and-severity-of-liver-fibrosis-in-metabolic-dysfunction-associated-fatty-liver-disease
#16
JOURNAL ARTICLE
Mohammadjavad Sotoudeheian
Metabolic dysfunction-associated Fatty Liver Disease (MAFLD) is a chronic liver disease characterized by the accumulation of fat in the liver and hepatic steatosis, which can progress to critical conditions, including Metabolic dysfunction-associated Steatohepatitis (MASH), liver fibrosis, hepatic cirrhosis, and hepatocellular carcinoma. Galectin-3, a member of the galectin family of proteins, has been involved in cascades that are responsible for the pathogenesis and progression of liver fibrosis in MAFLD...
May 7, 2024: Protein and Peptide Letters
https://read.qxmd.com/read/38715085/mimicking-chronic-alcohol-effects-through-a-controlled-and-sustained-ethanol-release-device
#17
JOURNAL ARTICLE
Wanil Kim, Jin-Ok Chu, Do-Yeon Kim, Soo-Hyeon Lee, Chang-Hyung Choi, Kyung-Ha Lee
Alcohol consumption, a pervasive societal issue, poses considerable health risks and socioeconomic consequences. Alcohol-induced hepatic disorders, such as fatty liver disease, alcoholic hepatitis, chronic hepatitis, liver fibrosis, and cirrhosis, underscore the need for comprehensive research. Existing challenges in mimicking chronic alcohol exposure in cellular systems, attributed to ethanol evaporation, necessitate innovative approaches. In this study, we developed a simple, reusable, and controllable device for examining the physiological reactions of hepatocytes to long-term alcohol exposure...
May 7, 2024: Journal of Biological Engineering
https://read.qxmd.com/read/38714084/sodium-arsenite-induces-hepatic-stellate-cells-activation-by-m-6-a-modification-of-tgf-%C3%AE-1-during-liver-fibrosis
#18
JOURNAL ARTICLE
Tianming Qiu, Kun Hou, Jingyuan Zhang, Ningning Wang, Xiaofeng Yao, Guang Yang, Liping Jiang, Jikun Dong, Menglong Miao, Jie Bai, Xiance Sun
The compound known as Sodium arsenite (NaAsO2 ), which is a prevalent type of inorganic arsenic found in the environment, has been strongly associated with liver fibrosis (LF), a key characteristic of nonalcoholic fatty liver disease (NAFLD), which has been demonstrated in our previous study. Our previous research has shown that exposure to NaAsO2 triggers the activation of hepatic stellate cells (HSCs), a crucial event in the development of LF. However, the molecular mechanism is still unknown. N6-methyladenosine (m6 A) modification is the most crucial post-transcriptional modification in liver disease...
May 6, 2024: Ecotoxicology and Environmental Safety
https://read.qxmd.com/read/38714040/intrahepatic-hypothyroidism-in-masld-role-of-liver-specific-thyromimetics-including-resmetirom
#19
REVIEW
Mohammad Shafi Kuchay, Scott Isaacs, Anoop Misra
BACKGROUND AND AIMS: Thyroid hormones are important regulators of hepatic lipid homeostasis and whole-body energy expenditure. Recent evidence suggests that euthyroid individuals with metabolic dysfunction-associated steatohepatitis (MASH) develop intrahepatic hypothyroidism that promotes progression of MASH. METHODS: A literature search was performed with Medline (PubMed), Scopus and Google Scholar electronic databases from inception till March 2024, using the following keywords: hypothyroidism and nonalcoholic fatty liver disease; MASLD and thyroid function; intrahepatic hypothyroidism; TRβ agonists; and resmetirom...
May 4, 2024: Diabetes & Metabolic Syndrome
https://read.qxmd.com/read/38712281/the-transcription-factor-znf469-regulates-collagen-production-in-liver-fibrosis
#20
Sebastian Steinhauser, David Estoppey, Dennis P Buehler, Yanhua Xiong, Nicolas Pizzato, Amandine Rietsch, Fabian Wu, Nelly Leroy, Tiffany Wunderlin, Isabelle Claerr, Philipp Tropberger, Miriam Müller, Lindsay M Davison, Quanhu Sheng, Sebastian Bergling, Sophia Wild, Pierre Moulin, Jiancong Liang, Wayne J English, Brandon Williams, Judith Knehr, Marc Altorfer, Alejandro Reyes, Craig Mickanin, Dominic Hoepfner, Florian Nigsch, Mathias Frederiksen, Charles R Flynn, Barna D Fodor, Jonathan D Brown, Christian Kolter
Non-alcoholic fatty liver disease (NAFLD) - characterized by excess accumulation of fat in the liver - now affects one third of the world's population. As NAFLD progresses, extracellular matrix components including collagen accumulate in the liver causing tissue fibrosis, a major determinant of disease severity and mortality. To identify transcriptional regulators of fibrosis, we computationally inferred the activity of transcription factors (TFs) relevant to fibrosis by profiling the matched transcriptomes and epigenomes of 108 human liver biopsies from a deeply-characterized cohort of patients spanning the full histopathologic spectrum of NAFLD...
April 25, 2024: bioRxiv
keyword
keyword
53395
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.